MMMaximilian Molitor

Maximilian Molitor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maximilian Molitor has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Radioiodination of Two Carborane‐Based Dual Cyclooxygenase‐2/5‐Lipoxygenase Inhibitors and Their In Vitro and In Vivo Evaluation

    by Jonas Schädlich, Martin Ullrich, Cathleen Haase‐Kohn, Robert Wodtke, Sebastian Braun, Maximilian Molitor, Bettina Hofmann, Dieter Steinhilber, Klaus Kopka, Evamarie Hey‐Hawkins, et al.

    Cyclooxygenase‐2 (COX‐2) and 5‐lipoxygenase (5‐LO) are key enzymes in prostanoid and leukotriene signaling and are overexpressed in various cancers, correlating with malignancy and metastasis. This renders them promising molecular targets for radiotracer development. In this study, isomeric closo ‐dicarbadodecaborane(12)‐based dual COX‐2/5‐LO inhibitors ( 1 and 2 ) served as scaffolds for iodine‐123‐labeling. Iodinated derivatives 3 and 4 inhibited 5‐LO more potently than COX‐2 in vitro ( IC 50 0.62 µM and 41.3 µM ( 3 ); 0.54 µM and 67.7 µM ( 4 )). Radioiodination yielded 39%–71% of [ 123 I]3 and [ 123 I]4 ; and the formulations were stabilized with antioxidants. Cellular uptake of [ 123 I]3 and [ 123 I]4 was evaluated in human cells with distinct COX‐2 and 5‐LO expression: U87 glioblastoma, HT‐29 colorectal carcinoma cells, THP‐1 monocytes (MC) and macrophages. Consistent with the observed inhibitory potency, the uptake of the radiotracers proved to be independent of COX‐2 expression. In contrast, it was influenced by 5‐LO expression in tumor but not inflammatory cells. Single‐photon emission computed tomography imaging in tumor xenograft mouse models revealed no tumor retention of [ 123 I]3 and [ 123 I]4 due to rapid metabolism via radiodeiodination. Despite successful radiosynthesis and in vitro evaluation of iodine‐123‐labeled COX‐2/5‐LO inhibitors, improved inhibitory activity and stability are required for development of suitable radiotracers.


  • Front Cover: Radioiodination of Two Carborane‐Based Dual Cyclooxygenase‐2/5‐Lipoxygenase Inhibitors and Their In Vitro and In Vivo Evaluation (ChemBioChem 7/2026)

    by Jonas Schädlich, Martin Ullrich, Cathleen Haase‐Kohn, Robert Wodtke, Sebastian Braun, Maximilian Molitor, Bettina Hofmann, Dieter Steinhilber, Klaus Kopka, Evamarie Hey‐Hawkins, et al.

  • Open Access

    Unlocking the potential: unveiling tyrphostins with Michael-reactive cyanoacrylate motif as promising inhibitors of human 5-lipoxygenase

    by Maximilian Molitor, Amelie Menge, Sebastian Mandel, Sven George, Susanne Müller, Stefan Knapp, Bettina Hofmann, Dieter Steinhilber, Ann-Kathrin Häfner

    Human 5-lipoxygenase (5-LO) is the key enzyme in the biosynthesis of leukotrienes, mediators of the innate immune system that also play an important role in inflammatory diseases and cancer. In this study, we present compounds, containing a Michael-reactive cyanoacrylate moiety as potent inhibitors of 5-LO. Representatives of the tyrosine kinase inhibitor family called tyrphostins, structurally related to known 5-LO inhibitors, were screened for their 5-LO inhibitory properties using recombinant human 5-LO, intact human PMNL (polymorphonuclear leukocytes), and PMNL homogenates. Their mode of action was characterized by the addition of glutathione, using a fourfold cysteine 5-LO mutant and mass spectrometry analysis. SAR studies revealed several members of the tyrphostin family containing a Michael-reactive cyanoacrylate to efficiently inhibit 5-LO. We identified degrasyn (IC50 0.11 µM), tyrphostin A9 (IC50 0.8 µM), AG879 (IC50 78 nM), and AG556 (IC50 64 nM) as potent 5-LO inhibitors. Mass spectrometry analysis revealed that degrasyn and AG556 covalently bound to up to four cysteines, including C416 and/or C418 which surround the substrate entry site. Furthermore, the 5-LO inhibitory effect of degrasyn was remarkably impaired by the addition of glutathione or by the mutation of cysteines to serines at the surface of 5-LO. We successfully identified several tyrphostins as potent inhibitors of human 5-LO. Degrasyn and AG556 were able to covalently bind to 5-LO via their cyanoacrylate moiety. This provides a promising mechanism for targeting 5-LO by Michael acceptors, leading to new therapeutic opportunities in the field of inflammation and cancer.


  • Open Access

    Novel Cannabinoid Receptor 2 (CB2) Low Lipophilicity Agonists Produce Distinct cAMP and Arrestin Signalling Kinetics without Bias

    by Raahul Sharma, Sameek Singh, Zak M. Whiting, Maximilian Molitor, Andrea J. Vernall, Natasha L. Grimsey

    Cannabinoid Receptor 2 (CB2) is a promising target for treating inflammatory diseases. We designed derivatives of 3-carbamoyl-2-pyridone and 1,8-naphthyridin-2(1H)-one-3-carboxamide CB2-selective agonists with reduced lipophilicity. The new compounds were measured for their affinity (radioligand binding) and ability to elicit cyclic adenosine monophosphate (cAMP) signalling and β-arrestin-2 translocation with temporal resolution (BRET-based biosensors). For the 3-carbamoyl-2-pyridone derivatives, we found that modifying the previously reported compound UOSS77 (also known as S-777469) by appending a PEG2-alcohol via a 3-carbomylcyclohexyl carboxamide (UOSS75) lowered lipophilicity, and preserved binding affinity and signalling profile. The 1,8-naphthyridin-2(1H)-one-3-carboxamide UOMM18, containing a cis configuration at the 3-carboxamide cyclohexyl and with an alcohol on the 4-position of the cyclohexyl, had lower lipophilicity but similar CB2 affinity and biological activity to previously reported compounds of this class. Relative to CP55,940, the new compounds acted as partial agonists and did not exhibit signalling bias. Interestingly, while all compounds shared similar temporal trajectories for maximal efficacy, differing temporal trajectories for potency were observed. Consequently, when applied at sub-maximal concentrations, CP55,940 tended to elicit sustained (cAMP) or increasing (arrestin) responses, whereas responses to the new compounds tended to be transient (cAMP) or sustained (arrestin). In future studies, the compounds characterised here may be useful in elucidating the consequences of differential temporal signalling profiles on CB2-mediated physiological responses.